Print（PDF/175KB） Apr. 30, 2025 Corporate

Sumitomo Pharma Announces Organizational Realignment and Personnel Changes

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and personnel changes, effective May 1, 2025.

Ⅰ. Organizational Realignment (effective May 1, 2025)

Corporate Department

Regenerative Medicine Office is renamed to Regenerative and Cellular Medicine Office.

Ⅱ. Changes in Personnel (effective May 1, 2025)

Corporate Department

Position as of May 1, 2025	Current position	Name
Representative Director, President and CEO, RACTHERA Co., Ltd. Corporate Officer, Regenerative and Cellular Medicine Office	Representative Director, President and CEO, RACTHERA Co., Ltd. Corporate Officer, Regenerative Medicine Office	Atsushi Ikeda
Representative Director, President and CEO, S-RACMO Co., Ltd. Corporate Officer, Regenerative and Cellular Medicine Collaboration	Representative Director, President and CEO, S-RACMO Co., Ltd. Corporate Officer, Regenerative Medicine Collaboration	Atsushi Tsuchida
Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative and Cellular Medicine Office	Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative Medicine Office	Koichiro Manabe
Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative and Cellular Medicine Office	Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative Medicine Office	Kenji Yoshida